These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19509160)

  • 1. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
    Rajeshkumar NV; Tan AC; De Oliveira E; Womack C; Wombwell H; Morgan S; Warren MV; Walker J; Green TP; Jimeno A; Messersmith WA; Hidalgo M
    Clin Cancer Res; 2009 Jun; 15(12):4138-46. PubMed ID: 19509160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
    Arcaroli JJ; Touban BM; Tan AC; Varella-Garcia M; Powell RW; Eckhardt SG; Elvin P; Gao D; Messersmith WA
    Clin Cancer Res; 2010 Aug; 16(16):4165-77. PubMed ID: 20682712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src inhibitors in early breast cancer: a methodology, feasibility and variability study.
    Jones RJ; Young O; Renshaw L; Jacobs V; Fennell M; Marshall A; Green TP; Elvin P; Womack C; Clack G; Dixon JM
    Breast Cancer Res Treat; 2009 Mar; 114(2):211-21. PubMed ID: 18409068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
    Green TP; Fennell M; Whittaker R; Curwen J; Jacobs V; Allen J; Logie A; Hargreaves J; Hickinson DM; Wilkinson RW; Elvin P; Boyer B; Carragher N; Plé PA; Bermingham A; Holdgate GA; Ward WH; Hennequin LF; Davies BR; Costello GF
    Mol Oncol; 2009 Jun; 3(3):248-61. PubMed ID: 19393585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
    de Vries TJ; Mullender MG; van Duin MA; Semeins CM; James N; Green TP; Everts V; Klein-Nulend J
    Mol Cancer Res; 2009 Apr; 7(4):476-88. PubMed ID: 19372577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
    Schweppe RE; Kerege AA; French JD; Sharma V; Grzywa RL; Haugen BR
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2199-203. PubMed ID: 19293266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Src impairs the growth of met-addicted gastric tumors.
    Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
    Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models.
    Pham NA; Magalhaes JM; Do T; Schwock J; Dhani N; Cao PJ; Hill RP; Hedley DW
    Int J Cancer; 2009 Jan; 124(2):280-6. PubMed ID: 18924149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
    Messersmith WA; Rajeshkumar NV; Tan AC; Wang XF; Diesl V; Choe SE; Follettie M; Coughlin C; Boschelli F; Garcia-Garcia E; Lopez-Rios F; Jimeno A; Hidalgo M
    Mol Cancer Ther; 2009 Jun; 8(6):1484-93. PubMed ID: 19509264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
    Chen J; Ouyang ZG; Zhang SH; Zhen YS
    Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.
    Fiebig HH; Schüler J; Bausch N; Hofmann M; Metz T; Korrat A
    Cancer Genomics Proteomics; 2007; 4(3):197-209. PubMed ID: 17878523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.
    Yun HS; Lee J; Kil WJ; Kramp TR; Tofilon PJ; Camphausen K
    Mol Cancer Ther; 2021 Sep; 20(9):1672-1679. PubMed ID: 34158343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
    Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
    Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
    Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
    Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
    Hennequin LF; Allen J; Breed J; Curwen J; Fennell M; Green TP; Lambert-van der Brempt C; Morgentin R; Norman RA; Olivier A; Otterbein L; Plé PA; Warin N; Costello G
    J Med Chem; 2006 Nov; 49(22):6465-88. PubMed ID: 17064066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma.
    Madan R; Smolkin MB; Cocker R; Fayyad R; Oktay MH
    Hum Pathol; 2006 Jan; 37(1):9-15. PubMed ID: 16360410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
    Hannon RA; Finkelman RD; Clack G; Iacona RB; Rimmer M; Gossiel F; Baselga J; Eastell R
    Bone; 2012 Apr; 50(4):885-92. PubMed ID: 22245630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells.
    Trevino JG; Gray MJ; Nawrocki ST; Summy JM; Lesslie DP; Evans DB; Sawyer TK; Shakespeare WC; Watowich SS; Chiao PJ; McConkey DJ; Gallick GE
    Angiogenesis; 2006; 9(2):101-10. PubMed ID: 16871430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.